GLP-1 Drugs for Parkinson’s: Lixisenatide Signal, Exenatide Miss
Parkinson’s disease is the second most common neurodegenerative disorder, affecting around 10 million people worldwide. The mental-health burden is heavy: depression affects 40-50% of patients9, anxiety 30-40%, sleep disorders most patients eventually, and dementia about a third of long-duration cases. Standard treatment with levodopa controls motor symptoms but doesn’t slow the underlying neurodegeneration. The clinical …